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Abstract
Background: Restoration of damaged tissues through the activation of endogenous progenitors is an attractive
therapeutic option. A deep evaluation of the intrinsic stem/progenitor cell properties as well as the reciprocal
interactions with injured environments is of critical importance.
Methods: Here, we show that bone marrow stromal cell antigen 2 (BST2) allows the isolation of a population of
circulating progenitors, the circulating healing (CH) cells, characterized by a distinctive core signature. The bone
marrow (BM) origin of BST2pos CH cells has been strengthened by the co-expression of leptin receptor, the hallmark
of a subpopulation of BM-skeletal stem cells.
Results: BST2pos CH cells retained the capacity to (i) respond to injury signals generated by a bone fracture, (ii)
modify the expression of cell motility genes following damage, and (iii) react to hepatocyte growth factor-activator
(HGFA), an injury-related stimulus sufficient to induce their transition into GALERT, a state in which cells are
functionally activated and participate in tissue repair.
Conclusions: Taken together, these results could pave the way for the identification of new strategies to enhance
and potentiate endogenous regenerative mechanisms for future therapies.
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Background
To date, clinical efforts towards tissue—and in particular
skeletal tissue—regeneration have focused on cell-based
therapies, including bone marrow- and adipose-derived
mesenchymal stromal cells (MSCs), or mature osteo-
blasts [1]. Despite initial encouraging results have been
obtained with the transplantation of exogenous progeni-
tors in different experimental models, their application
in the clinical setting is still hampered by skepticism,
fueled by problems regarding safety, immunogenicity,
and questionable engraftment/differentiation ability of
transplanted cells [2]. Following injury, the specific activa-
tion and mobilization of proper endogenous progenitors
could represent a significant furtherance in the field of
regenerative medicine, becoming the gist of future
therapeutic approaches. Therefore, in-depth functional
characterization of the activated and mobilized cells is a
matter of critical relevance in order to exploit them and
strengthen the body’s own regenerative potential [3].
Recent studies clearly indicate that discrete populations of
osteogenic progenitor cells exist, with distinctive identities
and specific differentiation abilities, suggesting both an al-
ternative hierarchical model and the existence of multiple
tissue-specific progenitors [4].
It is well known that a coordinated sequence of inter-
actions between the environments in which progenitor
cells reside in a quiescent state, namely specialized
niches, and the injury-associated signals can instruct the
cells migrating toward a damaged tissue [5, 6]. This is
mainly due to the peculiar ability of progenitor cells to
pick up extrinsic signals released by the niche as well as
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the injury, critically affecting their function [7, 8]. Un-
deniably, the activation of quiescent stem cells into the
cell cycle is a key step in initiating the process of tissue
repair [9, 10]. In this context, it has been recently shown
that a population of circulating progenitors, defined as
circulating healing (CH) cells, characterized by a
lineage-negative/CD45-negative (LinnegCD45neg) profile,
possess a strong chemotactic potential, being responsive
to the signals released by an injured environment as the
one generated by a bone fracture [11]. Indeed, these
stimuli direct their migration, with subsequent engraft-
ment and differentiation into specific cells belonging to
the affected tissue [11]. Here, we further implemented
the phenotypic characterization of LinnegCD45neg CH
cells and identified BST2 (bone marrow stromal cell
antigen 2, also called CD317), a lipid raft-associated
integral membrane protein, as a valuable CH cell
marker that allowed their identification and defined
their bone marrow (BM) compartmental origin.
BM-derived BST2posLinnegCD45neg cells co-expressed
the leptin-receptor (LepR) cell surface antigen,
hallmark of a subpopulation of quiescent adult
bone-forming MSCs [12]. BST2-expressing CH cells
maintained the capacity to (i) respond to injury environ-
mental cues, actively proliferating and migrating toward
the damaged site; (ii) modify the expression profile of spe-
cific cell motility-associated genes following the injury oc-
currence; and (iii) respond to the systemic factor
hepatocyte growth factor activator (HGFA), a stimulus
sufficient to induce the transition of multiple pools of qui-
escent progenitor cells into a GALERT state [13].
Methods
Mice
C57Bl/6 mice were purchased from Charles River La-
boratories (Calco, Italy). Red fluorescent protein-trans-
genic (RFP-Tg) mice (B6.Cg-Tg(CAG-DsRed*MST)
1Nagy/J) were purchased from the Jackson Laboratory
(Bar Harbor, MA, USA). We used female and male mice
between 6 and 8 weeks of age. Chimeric mice were gen-
erated using lethally irradiated C57Bl/6 mice that were
hematopoietically reconstituted with red fluorescent
protein-positive (RFPpos) syngeneic bone marrow nucle-
ated cells. Mice were bred and maintained at the Animal
Facility of “IRCCS Ospedale Policlinico San Martino.”
All animal procedures were approved by the “ IRCCS
Ospedale Policlinico San Martino” Ethical Committee
and performed in accordance with the national current
regulations regarding the protection of animals used for
scientific purpose (D. Lgs. 4 March 2014, n. 26,
legislative transposition of Directive 2010/63/EU of the
European Parliament and of the Council of 22 September
2010 on the protection of animals used for scientific
purposes).
Isolation of BST2pos CH cells
CH cells were isolated from the peripheral blood (PB)
and bone marrow (BM) of not-fractured (naive)
wild-type (WT) and RFP-Tg mice, fractured mice at
different times post-fracture induction (24, 36 h), and
mice intravenously injected with recombinant hepato-
cyte growth factor activator (rHGFA) (24 and 36 h
post-injection). Mice were anesthetized with an intraper-
itoneal (i.p.) injection of 100 μl/20 g body weight of
stock solution containing ketamine HCl (100 mg/kg)
and xylazine (10 mg/kg). PB was harvested from the
retro-orbital vein and collected into heparin-coated
tubes. BM cells were collected by flushing nucleated
cells out of the femurs and tibiae with cold
phosphate-buffered saline (PBS). Whole PB samples
were lysed twice using a BD Pharm Lyse (BD Biosci-
ences, Milan, Italy). Whole BM samples were lysed once
using the same BD Pharm Lyse. Peripheral blood mono-
nuclear cells (PBMCs) derived from each experimental
group were pooled together (at least three mice/group)
and stained for fluorescence-activated cell sorting
(FACS) analysis. Similarly, BM-derived nucleated cells
derived from each experimental group were pooled
together (at least three mice/group) and stained for
FACS analysis. Experiments were repeated at least six
times.
FACS and cell sorting
To determine the amount of BST2posLinnegCD45neg
cells, PBMCs and BM cells derived from fractured and
naive mice were collected in FACS buffer (PBS contain-
ing 2% heat-inactivated fetal bovine serum) and stained
for 10 min at 4 °C with PerCP-Cy5.5-conjugated Lineage
Antibody Cocktail (BD Biosciences). After washing, cells
were stained with APC rat anti-mouse CD45 antibody
(clone 30-F11) (BD Biosciences) and with PE-Cy7 rat
anti-mouse BST2 antibody (clone eBio927) (eBioscience,
San Diego, CA, USA). BM-derived BST2posLinnegCD45-
neg cells were also stained with the mouse Leptin R bio-
tinylated antibody (Accession # Q3US58) (R&D Systems,
Minneapolis, MN, Toll Free USA, Canada). A streptavi-
din Alexa Fluor 488 (Molecular Probes) was used for
indirect staining to detect the biotinylated antibody. The
percentage of BrdUpos cells was analyzed using the PE
anti-BrdU antibody (clone BU20A) (eBioscience) in
combination with the FoxP3/Transcription Staining
Buffer Set (eBioscience).
Fluorescence Minus One (FMO) controls were
performed for each combination in order to set the best
threshold in (sub)gating of BST2pos, LepRpos, and
BrdUpos subsets. A set of microsphere suspensions (2,
4, 6 μm) (Molecular Probes, Milan, Italy) was used as
size references. BST2pos CH cells were sorted with
high purity mask, from naive and RFP-Tg mice. All
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experiments were performed on BD FACSAria II.
Data were analyzed using BD FACSDiva software.
Mouse femoral fracture model and BST2pos CH cell injection
All surgical procedures were performed under anesthesia
and normal sterile conditions. The injury model was
performed as previously described [11]. The mice
received post-operative analgesia (Buprenorphine
0.1 mg/kg), and unprotected weight-bearing was allowed
immediately post-operation. One hundred and fifty thou-
sand RFPposBST2pos CH cells were intravenously (i.v.)
injected in four syngeneic WT mice 24 h post-fracture
induction and in three syngeneic WT mice 40 days
post-fracture induction.
Cell quantification analysis
Cells present within the hard callus or knee region of
fractured and cell-injected mice were counted with the
ImageJ cell counting plugin. Three sections per animal
were quantified. Results were expressed as percentage of
cells for field.
HGFA and BrdU administration
Purified recombinant-active HGFA (R&D systems,
#1200-SE) was administered via intravenous tail vein
injection in naive C57Bl/6 mice (N = 4) at a dose of 1 μg
diluted into 100 μl of sterile PBS (vehicle solution).
Control injections were performed using 100 μl of
vehicle solution.
For BrdU incorporation assays, naive, fractured, or
HGFA-injected mice (at least three mice each group)
were given an i.p. injection of BrdU Labeling Reagent
(Invitrogen) (10 μl/g body weight) every 8 h for 36 h.
The frequency of BrdUpos cells was then analyzed by
flow cytometry, as previously described.
Serum isolation and HGFA concentration
Serum was isolated from blood samples collected from
the retro-orbital vein of both naive (n = 4) and fractured
mice (24 h post-lesion induction) (n = 4). Blood was left
to clot for 1 h at room temperature. The clot was
removed by centrifugation (2000×g for 10 min, 4 °C), the
serum was isolated by removing the upper clear layer of
the blood sample, and it was maintained at − 80 °C until
use. Serum HGFA levels were measured using the
Mouse Hepatocyte growth factor activator (HGFAC)
ELISA kit (Cusabio Biotech). Each replicate measure-
ment represents a biologic replicate serum sample.
RNA extraction, PCR array, and qPCR analysis
Total RNA was extracted from sorted BST2pos CH cells
derived from the PB and BM collected from naive,
fractured (24 h post-lesion), and rHGFA-injected (24 h
post-injection) mice using the RNeasy® Micro Kit
(Qiagen, Milano, Italy) according to the manufacturer’s
instructions. Noteworthy, BST2pos CH cells were isolated
only from the bone marrow flushed from the fractured
leg. For the reverse transcription (RT) reactions and
cDNA synthesis, 0.5 μg of total RNA was used in the
RT2 First Strand kit (Qiagen) following the manufac-
turer’s instructions. The simultaneous expression profile
of 84 key genes involved in cell motility was evaluated
using the RT2 Profiler PCR Array Mouse Cell Motility
(Qiagen) analysis using the PE ABI PRISM 7700 se-
quence detection system (Perkin-Elmer, Waltham, MA)
and RT2 Sybr Green Mastermix (Qiagen). To validate
the expression profile of selected genes, we performed a
qPCR analysis. Each gene was tested on samples derived
from 10 mice, and three independent experiments were
performed. Primer sequences were designed using the
NCBI Primer-Blast tool (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/). Gene expression levels were nor-
malized using GAPDH as endogenous control by applying
the 2−ΔΔCt method. Primer sequences were as follows:
Hgf (FW. GGGATTCGCAGTACCCTCAC; REV. TCGG
ATGTTTGGGTCAGTGG); Fgf2 (FW. GAGAAGAGC
GACCCACACG; REV. ACACACTTAGAAGCCAGCA
GC); Igf1 (FW. GAAGCGATGGGGAAAATCAGC; REV.
CGCCAGGTAGAAGAGGTGTG); Met (FW. AGGA
CAAGACCACCGAGGAT; REV. CCTCTGCACCAAGG
ACAACA); Mmp9 (FW. GCGTCATTCGCGTGGATAA
G; REV. TGGAAACTCACACGCCAGAA); Dpp4 (FW.
CTGGTGTGGATTTCCAAGCAAT; REV. AGCT
ATGGAGAGCTATGCTGTG); Ezr (FW. GAGGTAGAA
GAGTGGCAGCA; REV. CCTCCTGCACGTGGTAATT
CA); uPar (FW. GACCTCTGCAGGACTACCGT; REV.
CATGGAGCCCATGCGGTAAC).
Analysis of microarray gene expression profiling data
We used a previously generated dataset to identify genes
associated with LinnegCD45neg CH cells isolated from
the peripheral blood of naive mice (accession number:
GSE64835). CH cell dataset was normalized to a
collection of 33 publicly available microarray datasets
corresponding to (i) three samples of an embryonic stem
cell line (ESC l.) and three samples of very small
embryonic-like (VSEL) stem cells (accession number:
GSE29281), (ii) 12 samples of hematopoietic stem cells
(HSC) at different stages of differentiation derived from
GSE27787 and GSE47935 datasets, (iii) six samples of
hemangioblasts (HEM) derived from dataset GSE43042,
and (iv) three ESC primary culture (ESC) samples, three
samples of multipotent adult progenitor cells (MAPC),
and three samples of bone marrow-derived mesenchymal
stromal cells (MSC) (accession number: GSE6933).
Normalization of CH cell dataset with the abovementioned
datasets was performed using RMA algorithms with
quantile normalization implemented in R/BioConductor.
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Statistically significant expression changes between CH
cells and selected comparison populations were based on
pairwise comparisons and were determined using Signifi-
cance Analysis of Microarrays (SAM) implemented in
TMEV. For each pairwise comparison, genes regulated at
least twofold were considered and the delta value was set
to return a false discovery rate (FDR) of zero. After, those
probes with fold change more than two, in any of the six
pairwise comparisons, were selected to explore overlapping
differentially upregulated genes among CH cells and the
other selected populations by VENNTURE software
(http://www.nia.nih.gov). The resulting 87 significantly up-
regulated genes were also visualized by hierarchical
clustering using Pearson correlation and average link-
age. Gene enrichment analysis was performed using
EnrichR online tool.
Immunofluorescence staining
To evaluate the migratory capacity through damaged
tissues of PB-derived RFPposBST2pos CH cells, bilateral
legs derived from fractured and cell-injected WT mice
(n = 3), from fractured and PBS-injected WT mice (n = 3),
were harvested 24 and 40 days post-lesion induction.
Bone samples were decalcified with a decalcifying
solution (0.5 M EDTA, pH 7.5) for 24 h at 4 °C and
cryoprotected with an ice-cold cryoprotection solution
(20% sucrose, 2% polyvinylpyrrolidone) for 24 h at 4 °C.
After washing with PBS, bone samples were embedded
in OCT compound, snap frozen in liquid nitrogen, and
stored at − 80 °C for immunofluorescence analysis. Sec-
tions of 5 μm were permeabilized with 0.3% Triton
X-100 for 20 min and treated with a blocking buffer (1×
PBS/5% normal goat serum/0.3% Triton X-100) for
60 min. Immunofluorescence staining was performed
using a polyclonal anti-RFP antibody (Abcam) followed
by goat anti-rabbit Alexa Fluor 633-conjugated second-
ary antibody (Thermo Scientific) and using a Runx2
rabbit mAb (Cell Signaling Technology, Milano, Italy)
and a rabbit anti-mouse type II collagen polyclonal anti-
body (Millipore), both of them followed by a Alexa Fluor
594-conjugated goat anti-rabbit IgG secondary antibody
(Thermo Scientific, Rockford, IL, USA). A DAPI solution
was applied for 5 min for nuclear staining. Images were
captured using an Axiovert 200 M microscope (Zeiss,
Germany). Pre-immune controls have been performed.
Statistical analysis
Assuming a Gaussian distribution of the data, we have
used unpaired t test for the statistical analysis of
differences between two groups and ordinary one-way
ANOVA associated with Dunnett’s multiple comparisons
test for analyzing differences among three or more
groups. Statistical significance was set at p < 0.05. All
statistical analyses were performed using GraphPad
Prism Version 6.0a (GraphPad Software, La Jolla, CA,
USA). The data analysis web portal at http://www.qia-
gen.com/geneglobe was applied to analyze PCR array
datasets.
Results
Core signature of CH cells
We have previously reported the existence of a rare
sub-population of circulating progenitors, LinnegCD45neg
CH cells, actively participating in the fracture healing
process and possessing a peculiar transcriptional expres-
sion pattern [11]. Despite the insights gained from this
genome-wide analysis, the distinctive core signature of
CH cells remained elusive. Here, we provide an integra-
tive data analysis by comparing the already published
transcriptome dataset of highly purified CH cells isolated
from peripheral blood (PB) of naive mice (Fig. 1a) with
publicly available profiles of other stem/progenitor cells
characterized by different stemness degree and capabil-
ities to enter the blood flow, including embryonic stem
cells (ESC), very small embryonic-like stem cells (VSEL),
hematopoietic stem cells (HSC), hemangioblasts (HEM),
multipotent adult stem cells (MAPC), and bone marrow
stromal cells (BMSC) [11]. To detect genes differentially
expressed in CH cells, a Significance Analysis of Micro-
array (SAM) algorithm was applied for the six pairwise
class comparisons, employing CH cell dataset as refer-
ence group (Additional file 1: Figure S1a–f ). By means
of VENNTURE [14], the analysis of the significantly up-
regulated genes (fold change > 2, FDR 0%) derived from
each pairwise comparison allowed to single out a CH
cell associated core signature composed of 87 character-
izing genes (Fig. 1b). The actual intensity values on a
log2 scale for each considered cell population underlies
how these 87 genes are upregulated in CH cells with
values ranging from 5.4 to 11.3 (Fig. 1c, Additional file 2:
Table S1 and Additional file 3: Table S2). Unsupervised
hierarchical clustering using Pearson correlation and
average linkage revealed the distance of CH cells from
the other populations, as identified by the length of the
dendrogram branches (Fig. 1d and Additional file 4).
Gene Ontology Enrichment Analysis (GOEA) identified,
within the set of upregulated transcripts, 30 genes be-
longing to “extracellular region” and “plasma membrane”
gene ontology categories (adherens junction, anchoring
junction, cell surface, focal adhesion, cell-substrate adhe-
rens junction, cell-substrate junction, membrane coat,
cell-cell junction). In particular, due to its recent identifi-
cation as one of the key genes defining human bone
marrow-mesenchymal stromal cell signature [15], we
focused on Bst2 (bone marrow stromal cell antigen 2), a
gene encoding for a cell surface antigen whose expres-
sion was validated by quantitative real-time PCR
(Fig. 1e).
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BST2 is an effective marker for CH cells
As a step toward picking out BST2 as valuable cell
surface antigen characterizing LinnegCD45neg CH cells,
we used a flow cytometry approach similar to the one
previously adopted to isolate these progenitors from the
peripheral blood of adult mice [11]. Since CH cells
represent a small-sized cell population with a diameter
ranging from 2 to 6 μm [11], a specific dimensional gate
(DG) has been delineated defining cutoff gates of 2, 4,
and 6 μm using appropriate microsphere suspensions
(Fig. 2a). An average of 14% events falling within the
considered DG expressed BST2, as indicated in Fig. 2b
(see also Additional file 1: Figure S2a, S2b). We then
fractioned BST2-positive (BST2pos) events by differential
expression of both CD45 and lineage markers, and we
recognized the presence of BST2posLinnegCD45neg cells
resembling CH cells (Fig. 2c). However, BST2 antigen is
also expressed by other two circulating sub-populations,
the type I interferon (IFN)-producing cells (IPC), charac-
terized by a LinposLy-6Cpos phenotype and a subset of
CD19posCD45pos plasma cells [16, 17]. To rule out the
presence of contaminating IPC or plasma cells, we evalu-
ated the co-expression of CD19 and Ly6C within the gate
of interest (BST2posLinnegCD45neg). No BST2posCD19pos or
Fig. 1 Transcriptome analysis reveals a core signature of CH cells. a Schematics illustrating isolation of CH cells from the PB of naive C57Bl/6 mice
for transcriptome analysis. b Venn diagram identifying the common genes resulting from pairwise comparisons between CH cells (n = 2), used as
reference group, and ESC (blue), (n = 6), BM-MSC (yellow) (n = 3), HEM (gray) (n = 6), VSEL (green) (n = 3), HSC (purple) (n = 12), and MAPC (light
blue) (n = 3). c The histogram shows the log2 array intensity distribution of the 87 genes significantly upregulated in CH cells in comparison to
the abovementioned cell populations. d Heat map showing the z-transformed expression values of the selected 87 genes together with their
clustering into the “extracellular region” and “plasma membrane” gene ontology (GO) categories, indicated in blue. The genes not comprised in
these two GO categories are indicated in green. e The significant expression of Bst2 gene in CH cells was confirmed by quantitative PCR analysis,
comparing the gene expression with BM-MSC and ESC (t value = 13.77, degree of freedom (df) = 7 and t value = 9.43, df = 7, respectively).
****p < 0.0001. Three independent replicates for each experimental group have been analyzed
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BST2posLy6Cpos events were present in the LinnegCD45neg
population (Fig. 2d). As expected, Ly6Cpos cells fell within
the BST2posLinpos events, whereas the few CD19pos cells
within the LinnegCD45pos events (Fig. 2e).
To be de facto regarded as CH cells, other connotative
functional characteristics have to be shared by
PB-derived BST2posLinnegCD45neg cells, that is, the
capacity to be specifically mobilized toward an injured
site and the ability to integrate into the specific tissue.
We tested the cell homing capacity taking advantage of
the same stabilized, transverse, mid-diaphyseal femoral
fracture model previously adopted [11] (Fig. 2f ). To
Fig. 2 Small-sized BST2posLinnegCD45neg cells circulate in the peripheral blood and engraft within injured bone and cartilage. a–c Representative
flow cytometry strategy used to identify BST2posLinnegCD45neg cells in the peripheral blood of C57Bl/6 mice (6 mice/experimental replicate;
n = 15 independent experiments). DG, dimensional gate. BST2posLinnegCD45neg cells (Q1) (d) as well as the sum of events falling within the
BST2posLinnegCD45neg cells (Q1), BST2posLinnegCD45pos cells (Q2), and BST2posLinposCD45pos cells (Q3) (e) were stained with the B lymphocyte
marker CD19 and the macrophage/dendritic cell precursor marker Ly6C. The peripheral blood of 30 naive C57Bl/6 mice (n = 5 independent
experiments) has been considered. f Serial immunofluorescence sections (magnification × 5) from the resulting callus formed 24 days after the
osteotomy. #knee, °° hard callus. g–l Double fluorescence images showing signals from DAPI (blue) and RFP (red) in the hard callus (g), in the
contralateral femur (h), in the articular cartilage (j), and in the contralateral articular cartilage (k) of fractured mice that received RFPpos CH cell
injection 24 h post-fracture induction. Femur and articular cartilage of fractured and PBS-injected mice (i and l, respectively) were used as
negative controls. Five mice/experimental group have been used. m–r Double fluorescence images showing signals from DAPI (blue) and RFP
(red) in the hard callus (m), in the contralateral femur (n), in the articular cartilage (p), and in the contralateral articular cartilage (q) of fractured
mice that received RFPpos CH cell injection 40 days post-fracture induction. Femur and articular cartilage of fractured and PBS-injected mice
(o and r, respectively) were used as negative controls. Three mice/experimental group have been used. Magnification × 40, scale bar 50 μm
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trace their fate, BST2posLinnegCD45neg cells have been
sorted from red fluorescence protein (RFP)-transgenic
mice using the same flow cytometry strategy described
above (Additional file 1: Figure S2c–g), and RFPposBST2-
posLinnegCD45neg cells were intravenously (i.v.) injected
in fractured mice 24 h post-lesion induction, during the
acute phase response of the host to the injury event.
After 24 days, when a hard callus was completely formed
[18], we detected the presence of RFPpos cells inter-
spaced in the bone matrix belonging to the hard callus,
as well as in the articular cartilage of fractured and
cell-injected mice (Fig. 2g, j and Additional file 1:
Figure S3a–h). Indeed, with regard to the presence of
RFPpos cells in the articular cartilage, it is to note that
also this tissue was damaged during the surgical pro-
cedure, due to the insertion of the needle stabilizer.
On the contrary, no RFPpos cells have ever been de-
tected either in the contralateral femurs of the same
fractured and cell-injected mice or in the femurs of
fractured and PBS-injected mice (Fig. 2h, i, k, l). The spe-
cificity of the anti-RFP antibody has been evaluated in sec-
tions of bone tissue derived from RFP-transgenic mice, as
shown in Additional file 1: Figure. Moreover, injected
BSTpos-CH cells present in the hard callus of fractured
mice co-expressed the early osteogenic transcription fac-
tor Runx2 (Fig. 3a–d and Additional file 1: Figure S3i–l),
while BSTpos-CH cells detected in the articular cartilage
co-expressed type II collagen (Col II) (Fig. 3e–h and
Additional file 1: Figure S3m–p), indicating their differen-
tiation capability. When RFPposBST2posLinnegCD45neg cell
transplantation was delayed to 40 days post-lesion induc-
tion, when an advanced remodeling phase has been
reached and the molecular signals released by the injury
event go to wane, transplanted cells did not ever migrate
toward damaged tissues (Fig. 2m, p), clearly indicating that
the timing of transplantation significantly affected the
transplanted cell fate.
Taken together, these results reveal that (i) BST2 can
be considered as a worthy identifying marker for CH
cells, thus confirming the microarray data, and (ii)
BST2pos CH cells migrate to and engraft in wounded
skeletal tissues only when transplanted during the acute
phase response, in agreement with the concept that
factor(s) released during this period are directly involved
in progenitor cell activation.
BST2pos CH cells originate from the bone marrow and are
specifically activated under injury conditions
The major source of adult progenitors circulating in the
PB is bone marrow (BM) [19]. Transplantation of syn-
geneic RFP-expressing BM cells into lethally irradiated
mice has been used to verify the compartmental origin
Fig. 3 GFPpos BST2pos-CH cells differentiate into tissue-specific cells. BST2pos-CH cells, isolated from the peripheral blood of GFP-transgenic naive
mice and intravenously injected in syngeneic WT mice are able to engraft and differentiate in bone and cartilage tissue-specific cells, 24 days
after. a–d Serial fluorescence images showing signals from DAPI (blue) (a), endogenous GFP (green) (b), and anti-Runx2 (red) (c) in the hard callus
of fractured cell-injected mice. Overlap between DAPI, GFP, Runx2 is shown in panel d. White inset boxes in the panels show a higher
magnification of representative cells co-expressing DAPI, GFP, and Runx2 signals. e–h Serial fluorescence images showing signals from DAPI (blue)
(e), endogenous GFP (green) (f), and anti-Col II (red) (g) in knee region of fractured cell-injected mice. Overlap between DAPI, GFP, and Col II is
shown in panel h. White inset boxes in the panels show a higher magnification of representative cells co-expressing DAPI, GFP, and Col II signals.
Magnification × 40, scale bar 50 μm
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of circulating BST2pos CH cells (Fig. 4a). Using the same
flow cytometry approach described in Fig. 2a, it has been
shown that BST2pos CH cells isolated from the PB of
chimeric mice were RFP-positive (RFPpos), indicating a
BM origin (Fig. 4b). To confirm this, BST2pos CH cells
were detected in the BM of the same naive mice (Fig. 4c,
left panel). CH cells retain distinctive features which are
(i) the BM origin, (ii) the specific expression of BST2,
and (iii) the ability to be specifically mobilized toward
injured skeletal tissues. We therefore checked for the
expression of leptin receptor (LepR), a marker used for
the prospective identification of a subpopulation of skel-
etal stem cells [12]. More than 80% of BM-derived
BST2pos CH cells are LepR-positive (LepRpos), clarifying
the factual nature of CH cells as early progenitors con-
tributing to the fracture repair process (Fig. 4c, right
panel).
To gain further insight into what distinguishes
BST2pos CH cells derived from PB and BM, and what
dictates their responsiveness to injury-related signals, we
Fig. 4 BST2pos CH cells originate from bone marrow (BM) and modify their expression profile upon injury. a Schematic depicting the
experimental procedures followed to analyze PB-derived cells in chimeric mice. b Representative flow cytometry analysis of BST2pos CH cells
recovered from the PB of chimeric mice (8 mice/experimental replicate; n = 3 independent experiments). c Leptin receptor (LepR) expression by
BM-derived BST2posLinnegCD45neg CH cells (6 mice/experimental replicate; n = 3 independent experiments). Area under pink line identifies cells
reacting with specific antigen. Area under gray line indicates the Fluorescence Minus One (FMO) control. d–g Total RNA samples derived from
BST2pos CH cells isolated from the PB (n = 13) and BM (n = 10) of naive (PB-Naive and BM-Naive, respectively) and 24 h fractured (PB-Fracture
(n = 13) and BM-Fracture (n = 10), respectively) mice and qRT-PCR assays were performed using Cell Motility RT2 Profiler PCR Array (3 independent
experimental replicates). Each scatter plot compares the Log10 normalized expression of every gene on the array between PB-Naive (test group)
and BM-Naive (reference group) (d), BM-Fracture (test group) and BM-Naive (reference group) (e), PB-Fracture (test group) and PB-Naive
(reference group) (f), and PB-Naive (test group) and BM-Fracture (reference group) (g). The dashed lines indicate the diagonal and twofold
change between each comparison. For each pairwise comparison, black points indicate unchanged gene expressions, pink points indicate
upregulated genes, and blue points indicate downregulated genes in test groups
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investigated the profiles of a focused panel of genes in-
volved in cell motility and activation differentially
expressed by four experimental groups that are BST2pos
CH cells isolated from (i) PB of naive, not-fractured
mice (PB-Naive); (ii) PB of fractured mice, 24 h
post-lesion induction (PB-Fracture); (iii) BM of naive,
not-fractured mice (BM-Naive); and (iv) BM of fractured
mice, 24 h post-lesion induction (BM-Fracture). Gene
expression changes were evaluated by plotting the
normalized expression of each considered gene in one
condition against the other (Fig. 4d–g and Additional file 5:
Table S3). In this way, 36 genes resulted significantly
upregulated and 14 downregulated in BST2pos CH cells
derived from PB-Naive in comparison to BM-Naive
(Fig. 4d). Among the upregulated ones, four genes encod-
ing for fibroblast growth factor 2 (Fgf2), hepatocyte
growth factor (Hgf ), insulin-like growth factor 1(Igf1), and
the receptor Met caught our attention. FGF2, HGF, and
IGF1 are pleiotropic growth factors controlling cell prolif-
eration and migration [20–22]. MET, a receptor tyrosine
kinase that is activated by the binding of HGF, is required
for the specific activation of stem/progenitor cells into a
primed GAlert state in which they possess an enhanced po-
tential to activate themselves and promote tissue repair
[13]. On the contrary, 14 genes resulted over-expressed in
cells derived from the BM compartment, among which
the two cell adhesion molecules Dpp4 and Ezr, suggesting
the importance of adhesion interactions in the anchorage
and retention of quiescent progenitors to the bone
marrow environment (Fig. 4d). The comparison between
BST2pos CH cells derived from BM-Naive and
BM-Fracture led to similar results, with 35 genes signifi-
cantly over-expressed upon fracture, including the growth
factors and receptor mentioned above, and 10 downregu-
lated genes, comprising those encoding for cell-adhesion
molecules (Fig. 4e). These results suggest that the injury
event can trigger profound changes in the motility signa-
ture of CH cells. Almost identical profiles came out from
the comparison of PB-Naive and BM-Fracture, with the
exception of Dpp4 and Mmp9 that resulted significantly
downregulated in PB-Naive samples (Fig. 4f).
When we compared cells isolated from PB-Naive and
PB-Fracture, little variations in their gene expression pro-
files emerged (Fig. 4g). In particular, Mmp9, Fgf2, and
uPar were significantly upregulated in PB-derived cells be-
longing to fractured mice. The membrane receptor uPar
and the endopeptidase MMP9 have been described to play
important roles in physiological processes such as wound
healing [23, 24] and stem cell migration [25, 26], confirm-
ing once again that the damage event is associated with
variations in the expression profiles of those genes that
are involved in a rapid response to injury. Trends of se-
lected genes in the four experimental groups are reported
in Additional file 1: Figure S5a–d.
Systemic HGFA is a priming factor for BST2pos CH cell
functional response
It has been recently reported that in response to
injury-induced systemic signals, many stem/progenitor
cells reversibly transition between two functional cellular
phases, G0 and GALERT [13, 27]. During the GALERT state,
cells possess an increased capacity to activate and par-
ticipate in tissue repair processes. In particular,
HGF-activator (HGFA), the primary HGF protease, is in-
duced in response to injury and is one of the main fac-
tors responsible of this functional transition [13]. In
naive mice, BST2pos CH cells express significantly higher
levels of the HGF-receptor tyrosine kinase Met when
isolated from the PB than the BM (Fig. 4d). Similarly,
Met expression is significantly higher in BST2pos CH
cells sorted from the BM of fractured mice than in the
BM of naive mice (Fig. 4e). We tested whether the sera
of injured mice contained higher levels of HGFA by
ELISA. As reported in Fig. 5a, a significantly higher pro-
portion of HGFA was measured in injured sera analyzed
24 h post-fracture induction in comparison to sera iso-
lated from naive mice, suggesting a possible involvement
of this systemic factor in CH cell activation in response
to injury. To evaluate whether HGFA itself could mimic
the injury-generated environment, potentially regulating
the transition of BM-derived CH cells from a quiescent
to an activated state, either a femoral fracture or a single
administration of recombinant HGFA (rHGFA) was per-
formed 6 h after BrdU (5-bromodeoxyuridine) injection
in two parallel groups of animals. The BrdU injection
was repeated every 6 h, for a total of 36 h (Fig. 5b). As
measured by BrdU incorporation, BM-derived BST2pos
CH cells derived from fractured mice showed a signifi-
cantly higher propensity to cycle if compared to naive
control mice, and a similar trend was observed in cells
derived from rHGFA-injected mice (Fig. 5c). To confirm
the results obtained by PCR arrays, but also to assess the
injury-mimicking effects of rHGFA, we compared gene
expression profiles of the above-considered genes
derived from PB and BM of naive, fractured, and
rHGFA-injected mice (Fig. 5d–k). As expected, the
expression profiles of Hgf, Fgf2, and Igf1 were signifi-
cantly upregulated in cells isolated from PB-Naive and
from both PB- and BM-Fracture in comparison to the
cells isolated from the BM of naive control mice
(Fig. 5d–f ). rHGFA administration resembled the out-
comes prompted by bone fracture (Fig. 5d–f ). Similarly,
Met was over-expressed by BST2pos CH cells extracted
from PB-Naive, as well as from PB- and BM-Fracture
(Fig. 5g). Again, rHGFA administration induced in both
PB- and BM-derived cells a significant upregulation of
this receptor, recapitulating the fracture-induced effect
(Fig. 5g). As previously indicated by the PCR arrays,
genes encoding for the cell-adhesion molecules Dpp4
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and Ezr were significantly upregulated in cells extracted
from BM-Naive in comparison to the other considered ex-
perimental groups, comprising the ones derived from
rHGFA-injected mice (Fig. 5h, i). Finally, the genes encod-
ing for the proteolytic molecules uPar and Mmp9 were
over-expressed in PB-Fracture and PB-rHGFA-derived
cells (Fig. 5j, k). Collectively, these data indicate that (i)
the systemic factor HGFA induce the transition of CH
cells into a GALERT state, similarly to its reported effect on
other stem/progenitor cell populations, and (ii) injecting
mice with rHGFA is sufficient to induce a series of
molecular functional changes in BST2pos CH cells,
predisposing their functional response to injury.
Discussion
Our data support the conclusion that CH cells are an
endogenous source of progenitors characterized by a
unique core signature, originating from the bone
marrow compartment and expressing two characteristic
cell-surface antigens, BST2 and LepR.
BST2 is an antiviral antigen expressed by different
immune cell types that plays complex roles in the
Fig. 5 HGFA is sufficient to induce the GALERT transition and the functional molecular changes of BST2
pos CH cells. a Serum samples were
prepared from non-injured (naive) or 24 h injured (fractured) mice, and HGFA levels were measured by ELISA. Bar graphs represent mean ± SD
(t value = 4.62, df = 6). ** p = 0.0036. The serum from four mice/group have been analyzed. b Schematic depicting the timelines of BM-derived
BST2pos CH cell isolation from fractured or recombinant HGFA (rHGFA)-injected mice contemporary receiving consecutive BrdU injections. (c)
BM-derived BST2pos CH cells derived from fractured (gray bar) or rHGFA-injected (red bar) mice have higher propensity to cycle in vivo than cells
extracted from naive control mice (black bar). Three mice/experimental group have been used and four independent replicates have been
performed. Bar graphs represent mean ± SD (t = 3.11, df = 4) *p = 0.0357. d–k The expression of the selected motility-associated genes Hgf (d),
Fgf2 (e), Igf1 (f), Met (g), Dpp4 (h), Ezr (i), uPar (j), and Mmp9 (k) was confirmed by quantitative PCR analysis, comparing the gene expression
profiles of BST2pos CH cells isolated from PB- and BM-Naive (14 mice), PB- and BM-Fracture (12 mice), and PB- and BM-rHGFA mice (six mice).
Bar graphs represent mean ± SD, *p < 0.0306, **p < 0.0096, ****p < 0.0001
Lo Sicco et al. Stem Cell Research & Therapy           (2018) 9:300 Page 10 of 13
regulation of viral infection [28]. Recently, it has been
reported as one of the 28 CD marker genes that define
the molecular signature of human BM-derived MSCs
[15], being involved in their osteogenic differentiation
via the regulation of the BMP2 signaling pathway [29].
On the other hand, within the plethora of proposed
markers, LepR represents an undeniable antigen that ful-
fills the minimal criteria for defining a subpopulation of
skeletal stem cells [12]. LepR-expressing cells give rise to
osteoblasts and adipocytes during fetal development and
to chondrocytes only after a mechanical injury to articular
cartilage or following tibial fracture in adult mice [4, 12].
To the best of our knowledge, we here report for the
first time the existence of a rare population of
BM-derived progenitors co-expressing LepR and BST2,
the latter so far described only at mRNA level, traceable
in the circulation of naive mice in response to normal
physiological stimuli, and more importantly, activated
under injury conditions. CH cells share the distinctive
property of many adult progenitors to be retained in a
quiescent, non-cycling state, until they are needed for
maintaining tissue homeostasis or enhancing tissue re-
pair [30]. As previously reported by Joseph T. Rodgers
and colleagues, the stem cell quiescent state is composed
of two distinct functional phases, G0 and GALERT, among
which the cells transition in response to injury-induced
systemic signals [9]. In our experimental model, during
the acute phase response of the host to damage,
BM-derived CH cells start to proliferate and over-express
specific genes related to motility pathways, leading, in the
later phases of the healing process, to an efficient cell en-
graftment within the hard callus and the articular cartilage
of injured mice. Among the injury-regulated systemic fac-
tors, the active form of HGF (HGFA) possesses the pro-
cessing enzymatic activity of HGF and it is necessary and
sufficient to induce the GALERT transition of several stem/
progenitor cells [13].
The proof that injury induces the release of high levels
of HGFA in the serum and that CH cells significantly
over-express the gene encoding for the HGF-receptor
Met when they circulate in physiologic conditions or
when they are present in the bone marrow of injured
mice has suggested that HGFA could be also involved in
their priming. Indeed, the administration of a single dose
of rHGFA mimicked the fracture effects, prompting the
transitioning of CH cells to an alerted state and the
functional changes implicated in the complex events
underlying cell migration and activation. Nevertheless,
other signaling pathways could be implicated in the acti-
vation of CH cells. Among the others, the Wnt/β-ca-
tenin pathway has been described to play a key role in
the activation of tissue-resident stem cells, including
human bone marrow-derived MSCs [31], as well as in
the cell fate lineage specification in somatic stem cells
[32]. Moreover, it has been reported that injury signals
trigger the endogenous Wnt pathway, whose activation
is typically rapid and spatially restricted to the site of
damage [33].
Based on lineage tracing experiments, several stem/
progenitor cell identities have been proposed, often
with completely or partially overlapping characteristics
[34, 35]. Only recently, advances for identifying human
and mouse osteogenic progenitor cells have been reported
[12, 36]. As a whole, the data here presented focus on the
phenotypic and functional characterization of an endogen-
ous cell population, without any intention of demonstrat-
ing a factual and active involvement in the repair process,
in terms of enhancement of the repair itself. Many
challenges have to be overcome before the regeneration or
repair by endogenous progenitors can be succeeded.
Multidisciplinary approaches aiming at regulating the
proper migration, persistence, and differentiation of mobi-
lized cells, without over-activating the progenitor cell pool,
should be particularly important for developing novel and
reliable self-repair strategies.
Conclusions
Our collective data contribute to place CH cells as a
particularly interesting source of endogenous progeni-
tors with peculiar functional characteristics. The detailed
understanding of both local and systemic signals able to
skew the endogenous cell functional activities, perhaps
rendering them more responsive to extrinsic cues, could
open up new opportunities of advance in the transla-
tional regenerative medicine field.
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